Celyad Oncology SA (EBR:CYAD)
0.3110
-0.0080 (-2.51%)
Apr 30, 2026, 4:00 PM CET
Celyad Oncology Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1.71 | 4.2 | 7 | 12.45 | 30.02 |
Cash & Short-Term Investments | 1.71 | 4.2 | 7 | 12.45 | 30.02 |
Cash Growth | -59.33% | -40.03% | -43.72% | -58.54% | 74.18% |
Accounts Receivable | 0.01 | 0.13 | 0.38 | 0.91 | 0.42 |
Other Receivables | 0.78 | 0.78 | 2.4 | 0.35 | 1.92 |
Receivables | 0.79 | 0.91 | 2.78 | 1.26 | 2.34 |
Inventory | - | 0.42 | - | - | - |
Prepaid Expenses | 0.26 | 0.95 | 1.26 | 0.67 | 1.69 |
Other Current Assets | 0.74 | 0.05 | 0.08 | 0.45 | 0.25 |
Total Current Assets | 3.5 | 6.52 | 11.12 | 14.83 | 34.29 |
Property, Plant & Equipment | - | 1.49 | 1.83 | 0.31 | 3.25 |
Goodwill | - | - | - | - | 0.88 |
Other Intangible Assets | 0.02 | 0.02 | 0.05 | 0.46 | 34.81 |
Long-Term Accounts Receivable | - | - | - | - | 2.21 |
Long-Term Deferred Charges | - | 0.38 | 0.34 | 0.41 | 0.47 |
Other Long-Term Assets | 0.79 | 1.52 | 2.94 | 3.72 | 4.03 |
Total Assets | 4.3 | 9.93 | 16.28 | 19.72 | 79.94 |
Accounts Payable | 0.51 | 1.23 | 1.24 | 4.75 | 6.61 |
Accrued Expenses | 0.38 | 0.44 | 0.5 | 1.39 | 2.13 |
Current Portion of Leases | - | 0.14 | 0.16 | 0.14 | 0.9 |
Current Unearned Revenue | 0.06 | 0.08 | 0.31 | 0.89 | 1.1 |
Other Current Liabilities | 0.87 | 0.95 | 0.73 | 3.26 | 3.09 |
Total Current Liabilities | 1.82 | 2.85 | 2.93 | 10.43 | 13.83 |
Long-Term Leases | - | 0.76 | 0.9 | 0.12 | 1.73 |
Pension & Post-Retirement Benefits | 0 | 0 | 0 | 0.01 | 0.05 |
Other Long-Term Liabilities | 0.04 | 5.81 | 6.14 | 4.84 | 20.69 |
Total Liabilities | 1.86 | 9.42 | 9.98 | 15.4 | 36.3 |
Common Stock | 9.22 | 8.22 | 32.95 | 78.59 | 78.59 |
Additional Paid-In Capital | - | - | - | 6.32 | 6.32 |
Retained Earnings | -363.37 | -364.2 | -358.37 | -349.95 | -309 |
Comprehensive Income & Other | 356.59 | 356.49 | 331.73 | 269.36 | 267.73 |
Shareholders' Equity | 2.44 | 0.51 | 6.3 | 4.32 | 43.64 |
Total Liabilities & Equity | 4.3 | 9.93 | 16.28 | 19.72 | 79.94 |
Total Debt | - | 0.91 | 1.06 | 0.26 | 2.63 |
Net Cash (Debt) | 1.71 | 3.3 | 5.95 | 12.19 | 27.39 |
Net Cash Growth | -48.16% | -44.59% | -51.22% | -55.49% | 101.43% |
Net Cash Per Share | 0.04 | 0.08 | 0.23 | 0.54 | 1.76 |
Filing Date Shares Outstanding | 44.76 | 41.43 | 41.43 | 22.59 | 22.59 |
Total Common Shares Outstanding | 44.76 | 41.43 | 41.43 | 22.59 | 22.59 |
Working Capital | 1.68 | 3.67 | 8.19 | 4.4 | 20.47 |
Book Value Per Share | 0.05 | 0.01 | 0.15 | 0.19 | 1.93 |
Tangible Book Value | 2.42 | 0.49 | 6.26 | 3.86 | 7.95 |
Tangible Book Value Per Share | 0.05 | 0.01 | 0.15 | 0.17 | 0.35 |
Machinery | 0.08 | 0.83 | 0.89 | 1.28 | 4.01 |
Leasehold Improvements | - | 0.64 | 0.64 | 0.18 | 4.06 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.